GLP-1藥物真的與眾不同嗎？從臨床、經濟到政策的三維度剖析

由Adelaide Health Technology Assessment（hOurHTA）主辦的線上會議「GLP-1療法真的與眾不同嗎？臨床、經濟與政策觀點」，邀集了三位專家從不同維度深入剖析GLP-1藥物（如Wegovy、Mounjaro）帶來的革命性影響與挑戰。這不僅是一場醫療科技評估的討論，更涉及未來全球醫療體系與健保政策的重新定義。

臨床觀點：超越減重的抗發炎代謝藥物

肥胖是慢性疾病，而非生活方式失敗

肥胖管理專科醫師Dr. Remon Eskandar強調，肥胖是一種慢性且漸進的生物學疾病，而非單純的生活方式失敗。

GLP-1的真正療效：遠超減重

臨床數據顯示，GLP-1藥物不僅能帶來16%～22%的減重效果，更重要的是，即使在沒有減輕體重的情況下，它也能降低20%的心血管疾病（如心臟病、中風）風險。

它的本質是針對心臟、腎臟和血管的抗發炎藥物，未來的目標是預防洗腎、心臟衰竭等高成本的末期併發症。

經濟觀點：龐大的預算衝擊與長期成本效益挑戰

澳洲的現狀：50億澳幣的潛在負擔

應用健康經濟學家Chris Schilling點出了現實的殘酷：在澳洲，目前已有超過25萬人自費使用GLP-1。若將此推廣至100萬名符合條件的病人，每年可能需要耗費50億澳幣，這相當於澳洲藥品給付計畫（PBS）每年總預算的25%。

成本效益評估的困境

儘管預防末期併合症能省錢，但在藥物高昂的單價與需要終身服用的前提下，目前尚需發展「疾病專屬決策模型」，來驗證未來10到20年的長期成本效益。這正是醫療科技評估在新興藥物評估上面臨的核心課題。

政策觀點：醫療需求與美容目的的灰色地帶

適應症跨度大，政策挑戰高

健康經濟與政策專家Prof. Andrew Mitchell提出了政策面的巨大挑戰：GLP-1的潛在適應症跨度極大，部分甚至遊走在醫療與美容的灰色地帶。

健保給付的難題

澳洲政府不太可能為「美容減重」買單。面對龐大的潛在使用人口，健保體系必須嚴格把關，設立明確的客觀指標與持續用藥標準，將資源精準投資在能獲得最大經健康生活品質校正生命年（QALY）的高風險族群上（例如：已有心血管病史的次級預防）。

真實世界的挑戰：停藥率與藥物可及性

會中的交流探討了一個關鍵痛點：雖然臨床試驗的停藥率僅4～5%，但真實世界中卻有高達15～50%的病人在一年內停藥並面臨復胖。這背後反映的可能是「藥物短缺」與「長期自費負擔過高」的雙重困境。

結論：平衡創新、療效與財政永續

GLP-1絕對是極具潛力的突破性療法，但要將其納入常規的健保或公共醫療給付，我們仍需要：

  • 更長期的真實世界數據
  • 更精密的健康經濟模型
  • 更嚴格的循序漸進給付策略

面對這個可能改變全球醫療體系的藥物，我們如何在「病人健康、醫療創新與健保財政」之間取得平衡？這不僅是醫療科技評估的議題，更是21世紀公共衛生政策的關鍵課題。

English version below

Is GLP-1 Really Different? A Clinical, Economic, and Policy Perspective

An online conference organized by Adelaide Health Technology Assessment (hOurHTA), titled ‘Is GLP-1 Therapy Really Different? Clinical, Economic, and Policy Perspectives,’ brought together three experts to examine from different angles the revolutionary impact and challenges brought by GLP-1 drugs (such as Wegovy and Mounjaro). This is not merely a discussion of health technology assessment, but touches on the future redefinition of global healthcare systems and reimbursement policies.

Clinical Perspective: Beyond Weight Loss—An Anti-inflammatory Metabolic Drug

Obesity as a Chronic Disease, Not a Lifestyle Failure

Dr. Remon Eskandar, an obesity management specialist, emphasizes that obesity is a chronic and progressive biological disease, not merely a lifestyle failure.

The True Efficacy of GLP-1: Far Beyond Weight Reduction

Clinical data shows that GLP-1 drugs not only deliver 16%–22% weight reduction, but more importantly, they can reduce the risk of cardiovascular diseases (such as heart disease and stroke) by 20% even without weight loss. The essential mechanism is an anti-inflammatory drug targeting the heart, kidneys, and blood vessels, with the future goal of preventing costly end-stage complications such as renal failure and heart failure.

Economic Perspective: Substantial Budget Impact and Long-Term Cost-Effectiveness Challenges

The Current Situation in Australia: A Potential 5 Billion AUD Annual Burden

Chris Schilling, an applied health economist, points out a harsh reality: in Australia, over 250,000 people currently self-pay for GLP-1. If expanded to 1 million eligible patients, the annual cost could reach 5 billion AUD, equivalent to 25% of the annual budget of the Pharmaceutical Benefits Scheme (PBS).

The Dilemma of Cost-Effectiveness Analysis

Although preventing end-stage complications can save money, given the high drug cost and the need for lifelong treatment, we currently need to develop ‘disease-specific decision models’ to verify long-term cost-effectiveness over the next 10 to 20 years. This is a core challenge in health technology assessment when evaluating emerging drugs.

Policy Perspective: The Gray Area Between Medical Need and Cosmetic Purpose

Broad Indication Scope, High Policy Challenges

Prof. Andrew Mitchell, a health economics and policy expert, points out a major policy challenge: GLP-1 has a vast potential scope of indications, some of which even blur the line between medical and cosmetic purposes.

The Reimbursement Dilemma

The Australian government is unlikely to fund ‘cosmetic weight reduction.’ Facing a massive potential user population, the healthcare system must strictly control access by establishing clear objective criteria and continuing treatment standards, directing resources precisely toward high-risk populations that can achieve the maximum quality-adjusted life years (QALY)—for example, secondary prevention in patients with established cardiovascular disease history.

Real-World Challenges: Discontinuation Rates and Drug Accessibility

Discussions at the conference explored a critical pain point: although clinical trial discontinuation rates are only 4–5%, real-world data shows 15–50% of patients discontinue within one year and face weight regain. This may reflect a dual challenge of ‘drug shortages’ and ‘high long-term out-of-pocket costs.’

Conclusion: Balancing Innovation, Efficacy, and Financial Sustainability

GLP-1 is undoubtedly a promising breakthrough therapy, but to integrate it into routine public healthcare or insurance reimbursement, we still need:

  • Longer-term real-world evidence
  • More sophisticated health economic models
  • Stricter step-wise reimbursement strategies

Facing a drug that could reshape the global healthcare system, how do we balance ‘patient health, medical innovation, and healthcare finances’? This is not only a health technology assessment issue but a key question in 21st-century public health policy.